An Attempt to Improve the Therapeutic Effect of Boron Neutron Capture Therapy Using Commonly Employed 10B-carriers Based on Analytical Studies on the Correlation Among Quiescent Tumor Cell Characteristics, Tumor Heterogeneity and Cancer Stemness

Overview

Journal J Radiat Res

Publisher Oxford University Press

Specialties Environmental Health
Oncology
Radiology

Date 2020 Jul 1

PMID 32601693

Citations 4

Authors

Shin-Ichiro Masunaga

Yu Sanada

Keizo Tano

Yoshinori Sakurai

Hiroki Tanaka

Takushi Takata

Minoru Suzuki

Koji Ono

Affiliations

Soon will be listed here.

Abstract

Based on our previously published reports concerning the response of quiescent (Q) tumor cell populations to boron neutron capture therapy (BNCT), the heterogeneous microdistribution of 10B in tumors, which is influenced by the tumor microenvironment and the characteristics of the 10B delivery carriers, has been shown to limit the therapeutic effect of BNCT on local tumors. It was also clarified that the characteristics of 10B-carriers for BNCT and the type of combined treatment in BNCT can also affect the potential for distant lung metastases from treated local tumors. We reviewed the findings concerning the response of Q tumor cell populations to BNCT, mainly focusing on reports we have published so far, and we identified the mode of BNCT that currently offers the best therapeutic gain from the viewpoint of both controlling local tumor and suppressing the potential for distant lung metastasis. In addition, based on the finding that oxygenated Q tumor cells showed a large capacity to recover from DNA damage after cancer therapy, the interrelationship among the characteristics in Q tumor cell populations, tumor heterogeneity and cancer stemness was also discussed.

Citing Articles

Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan: Real-world experiences over a 2-year period.

Takeno S, Yoshino Y, Aihara T, Higashino M, Kanai Y, Hu N Cancer Med. 2024; 13(11):e7250.

PMID: 38826090 PMC: 11145025. DOI: 10.1002/cam4.7250.

The impact of TP53 status of tumor cells including the type and the concentration of administered 10B delivery agents on compound biological effectiveness in boron neutron capture therapy.

Masunaga S, Sanada Y, Takata T, Tanaka H, Sakurai Y, Suzuki M J Radiat Res. 2023; 64(2):399-411.

PMID: 36763853 PMC: 10036103. DOI: 10.1093/jrr/rrad001.

Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies.

Zhu H, Liu X Front Oncol. 2021; 11:666340.

PMID: 34434889 PMC: 8381364. DOI: 10.3389/fonc.2021.666340.

Molecular Mechanisms of Specific Cellular DNA Damage Response and Repair Induced by the Mixed Radiation Field During Boron Neutron Capture Therapy.

Maliszewska-Olejniczak K, Kaniowski D, Araszkiewicz M, Tyminska K, Korgul A Front Oncol. 2021; 11:676575.

PMID: 34094980 PMC: 8170402. DOI: 10.3389/fonc.2021.676575.

References

Masunaga S, Ono K, Takahashi A, Ohnishi K, Ohnishi T, Suzuki M . Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status. Cancer Sci. 2003; 94(1):125-33. PMC: 11160248. DOI: 10.1111/j.1349-7006.2003.tb01363.x. View

Masunaga S, Liu Y, Tanaka H, Sakurai Y, Suzuki M, Kondo N . Radiosensitivity and Capacity to Recover from Radiation-Induced Damage in Pimonidazole-Unlabeled Intratumor Quiescent Cells Depend on Status. World J Oncol. 2017; 2(1):1-9. PMC: 5649882. DOI: 10.4021/wjon272w. View

LAJTHA L . ON THE CONCEPT OF THE CELL CYCLE. J Cell Comp Physiol. 1963; 62:SUPPL1:143-5. View

Barth R, Mi P, Yang W . Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018; 38(1):35. PMC: 6006782. DOI: 10.1186/s40880-018-0299-7. View

Masunaga S, Kimura S, Harada T, Okuda K, Sakurai Y, Tanaka H . Evaluating the Usefulness of a Novel B-Carrier Conjugated With Cyclic RGD Peptide in Boron Neutron Capture Therapy. World J Oncol. 2017; 3(3):103-112. PMC: 5649788. DOI: 10.4021/wjon477w. View

Masunaga S, Ono K, Takahashi A, Ohnishi T, Kinashi Y, Takagaki M . Radiobiological characteristics of solid tumours depending on the p53 status of the tumour cells, with emphasis on the response of intratumour quiescent cells. Eur J Cancer. 2002; 38(5):718-27. DOI: 10.1016/s0959-8049(01)00430-0. View

Hader M, Frey B, Fietkau R, Hecht M, Gaipl U . Immune biological rationales for the design of combined radio- and immunotherapies. Cancer Immunol Immunother. 2020; 69(2):293-306. PMC: 7000501. DOI: 10.1007/s00262-019-02460-3. View

Masunaga S, Ono K, Hori H, Suzuki M, Kinashi Y, Takagaki M . Potentially lethal damage repair by total and quiescent tumor cells following various DNA-damaging treatments. Radiat Med. 1999; 17(4):259-64. View

Masunaga S, Kasaoka S, Maruyama K, Nigg D, Sakurai Y, Nagata K . The potential of transferrin-pendant-type polyethyleneglycol liposomes encapsulating decahydrodecaborate-(10)B (GB-10) as (10)B-carriers for boron neutron capture therapy. Int J Radiat Oncol Biol Phys. 2006; 66(5):1515-22. DOI: 10.1016/j.ijrobp.2006.08.028. View

10.

Masunaga S, Nagasawa H, Uto Y, Hori H, Suzuki M, Nagata K . The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations. Int J Hyperthermia. 2005; 21(4):305-18. DOI: 10.1080/02656730500060574. View

11.

Masunaga S, Liu Y, Tanaka H, Sakurai Y, Suzuki M, Kondo N . Reducing intratumour acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumour cells and metastatic potential. Br J Radiol. 2011; 84(1008):1131-8. PMC: 3473837. DOI: 10.1259/bjr/38457938. View

12.

Masunaga S, Sakurai Y, Tanaka H, Tano K, Suzuki M, Kondo N . The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy. Springerplus. 2015; 3:128. PMC: 4320213. DOI: 10.1186/2193-1801-3-128. View

13.

Masunaga S, Matsumoto Y, Hirayama R, Kashino G, Tanaka H, Suzuki M . Significance of manipulating intratumor hypoxia in the effect on lung metastases in radiotherapy, with reference to its effect on the sensitivity of intratumor quiescent cells. Clin Exp Metastasis. 2009; 26(7):693-700. DOI: 10.1007/s10585-009-9268-5. View

14.

Masunaga S, Ono K, Suzuki M, Sakurai Y, Takagaki M, Kobayashi T . Repair of potentially lethal damage by total and quiescent cells in solid tumors following a neutron capture reaction. J Cancer Res Clin Oncol. 1999; 125(11):609-14. DOI: 10.1007/s004320050323. View

15.

Masunaga S, Liu Y, Sakurai Y, Tanaka H, Suzuki M, Kondo N . Usefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential. Int J Hyperthermia. 2012; 28(7):636-44. DOI: 10.3109/02656736.2012.714517. View

16.

Cheng Y, Weng S, Yu L, Zhu N, Yang M, Yuan Y . The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors. Integr Cancer Ther. 2019; 18:1534735419876345. PMC: 7242805. DOI: 10.1177/1534735419876345. View

17.

Masunaga S, Ono K, Takahashi A, Sakurai Y, Ohnishi K, Kobayashi T . Impact of the p53 status of the tumor cells on the effect of reactor neutron beam irradiation, with emphasis on the response of intratumor quiescent cells. Jpn J Cancer Res. 2002; 93(12):1366-77. PMC: 5926926. DOI: 10.1111/j.1349-7006.2002.tb01246.x. View

18.

Masunaga S, Nagasawa H, Sakurai Y, Uto Y, Hori H, Nagata K . The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy. Int J Hyperthermia. 2006; 22(4):287-99. DOI: 10.1080/02656730600708171. View

19.

Masunaga S, Ono K, Hori H, Kinashi Y, Suzuki M, Takagaki M . Modification of tirapazamine-induced cytotoxicity in combination with mild hyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells. Int J Hyperthermia. 1999; 15(1):7-16. DOI: 10.1080/026567399285819. View

20.

Masunaga S, Takahashi A, Ohnishi K, Nagata K, Suzuki M, Kashino G . Dependency of repair of radiation-induced damage on p53 status and efficient inhibition of the repair with wortmannin treatment in vivo, with reference to the effect on intratumor quiescent cell population. Oncol Rep. 2007; 18(6):1589-96. View